MedPath

A prospective non-randomized controlled study of integrated traditional Chinese and western medicine for moderately active systemic lupus erythematosus

Not Applicable
Conditions
Systemic lupus erythematosus
Registration Number
ITMCTR2100005063
Lead Sponsor
Zhejiang Chinese Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

1. Comply with the 2019 EULAR/ACR SLE classification standards;
2. Those who meet the TCM syndrome differentiation of heat toxin, blood stasis and kidney deficiency;
3.7 <= SLEDAI-2000 <=12 points and the current glucocorticoid dosage (calculated by prednisone) <= 1 mg/kg.d;
4. Those between the ages of 18 and 60;
5. Those who voluntarily participate in this trial and agree to sign the informed consent for entering the clinical research.

Exclusion Criteria

1. Neuropsychiatric lupus patients or lupus crisis patients;
2. Patients with severe diseases of target organs of various systems, mental illness, tumors and other diseases;
3. Patients who cannot tolerate the drug treatment of this study;
4. Pregnant and lactating women;
5. Patients who are participating in other clinical trials;
6. The researchers believe that other reasons are not suitable for clinical trials.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Systemic lupus erythematosus disease activity score;
Secondary Outcome Measures
NameTimeMethod
upusQoL quality of life;Number of severe infections;TCM syndrome score;Changes of biomarker indicators before and after treatment;
© Copyright 2025. All Rights Reserved by MedPath